Cancer Research Horizons, the innovation arm of Cancer Research UK, today announced a collaboration and option agreement with Incyte to accelerate the discovery of next-generation antibody therapeutics to treat myeloproliferative neoplasms (MPNs), a group of rare blood cancers.
Under the agreement, Cancer Research Horizons and Incyte will work together to further characterise a panel of lead antibodies with the potential to deliver a differentiated therapeutic approach compared to current treatments. These antibodies aim to address significant unmet needs for patients living with MPNs.
Cancer Research Horizons will lead the research activities, with Incyte providing strategic input. Cancer Research Horizons and Incyte will share the cost of the initial research activities equally, with Incyte fully funding certain later stages. Incyte has an exclusive option to license the resulting intellectual property for commercialisation.
Nick Tribble, Associate Director of Antibody Discovery, Cancer Research Horizons, said: “This collaboration exemplifies our mission to translate cutting-edge science into new treatments for patients. By combining Cancer Research Horizons’ antibody discovery expertise with Incyte’s deep experience in haematology, we aim to deliver innovative therapies that address unmet needs.”
ENDS
About Cancer Research Horizons
Cancer Research Horizons is the innovation engine of Cancer Research UK – the world's largest charitable funder of cancer research. It brings together world-leading minds, bold ideas and the right partners to bridge the gap between academic research and taking drugs to market. It focuses on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.
To date, it has played an instrumental role in forming over 90 start-ups. It has helped bring 14 cancer drugs to market, born out of Cancer Research UK's pioneering research. Through these drugs, it has enabled in excess of 6 million courses of treatment for cancer patients across the world.
With access to Cancer Research UK's network of 4,000 exceptional researchers, and £400m of annual research spend, it is a powerful partner in the fight to conquer cancer. By uniting its commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, data licensing and collaboration, spin-out creation, and offer a full spectrum of drug discovery and clinical capabilities.
Every penny it makes goes back into funding the next bold steps, to help bring forward the day when all cancers are conquered.
For more information and to get in touch with the team, visit cancerresearchhorizons.com.
Contact
Tim Bodicoat
Content Manager, Cancer Research Horizons
[email protected]